Skip to main content
. 2015 Oct 26;15:1092. doi: 10.1186/s12889-015-2424-8

Table 2.

Time lapse between VL and PKDL with respect to the drug used for VL treatment

Anti-leishmanial drug No. (%) patients Median time lapse after VL treatment (months) Range (months)
SAG 210 (93.33) 36 1–384
Amphotericin B 12 (5.33) 48 3.6–84
Miltefosine 3 (1.33) 21 12–36